Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAF
BRAF-V600 mutation
MSS
combination targeted therapy
dabrafenib
trametinib
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
02
2023
accepted:
28
03
2023
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
Metastatic BRAF
Identifiants
pubmed: 37213293
doi: 10.3389/fonc.2023.1166545
pmc: PMC10196488
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1166545Informations de copyright
Copyright © 2023 Piringer, Decker, Trommet, Kühr, Heibl, Dörfler and Thaler.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Cancer Res. 2014 Oct 15;20(20):5322-30
pubmed: 25139339
Clin Cancer Res. 2015 Apr 1;21(7):1639-51
pubmed: 25589619
N Engl J Med. 2010 Aug 26;363(9):809-19
pubmed: 20818844
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Oncologist. 2022 Dec 9;27(12):1034-1040
pubmed: 36239399
Clin Colorectal Cancer. 2014 Sep;13(3):164-71
pubmed: 25069797
Nature. 2012 Jan 26;483(7387):100-3
pubmed: 22281684
Cancer Res. 2017 Dec 1;77(23):6513-6523
pubmed: 28951457
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Cancer Discov. 2021 Mar;11(3):714-735
pubmed: 33318037
Ther Adv Med Oncol. 2022 Jun 16;14:17588359221105022
pubmed: 35747165
Cell. 2004 Mar 19;116(6):855-67
pubmed: 15035987
Front Oncol. 2021 Jun 23;11:601722
pubmed: 34249672
Cancer Discov. 2012 Mar;2(3):227-35
pubmed: 22448344
J Clin Oncol. 2023 May 10;41(14):2628-2637
pubmed: 36763936
N Engl J Med. 2012 Nov;367(18):1694-703
pubmed: 23020132
Clin Cancer Res. 2013 Feb 1;19(3):657-67
pubmed: 23251002
Cancer Discov. 2017 Jun;7(6):610-619
pubmed: 28363909
J Clin Oncol. 2008 Oct 20;26(30):4906-11
pubmed: 18794541
Nat Med. 2023 Feb;29(2):458-466
pubmed: 36702949
N Engl J Med. 2012 Jul 12;367(2):107-14
pubmed: 22663011
Cancer Res. 2005 Jul 15;65(14):6063-9
pubmed: 16024606
Lancet Oncol. 2012 Aug;13(8):773-81
pubmed: 22805291
Immunity. 2016 Mar 15;44(3):609-621
pubmed: 26944201
J Clin Oncol. 2020 Aug 20;:JCO2001225
pubmed: 32816630
NPJ Precis Oncol. 2018 Feb 20;2(1):5
pubmed: 29872723
Cancer Discov. 2018 Apr;8(4):428-443
pubmed: 29431699
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
Nat Med. 2022 Oct;28(10):2162-2170
pubmed: 36097219
Jpn J Clin Oncol. 2009 Jun;39(6):406-9
pubmed: 19389795
N Engl J Med. 2019 Oct 24;381(17):1632-1643
pubmed: 31566309
J Clin Oncol. 2020 Jan 1;38(1):11-19
pubmed: 31725351
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Clin Cancer Res. 2020 Sep 1;26(17):4599-4605
pubmed: 32571791
Biomark Cancer. 2015 Sep 06;7(Suppl 1):9-12
pubmed: 26396549
J Clin Oncol. 2015 Dec 1;33(34):4023-31
pubmed: 26392102
Eur J Cancer. 2012 Jul;48(10):1466-75
pubmed: 22446022
Lancet Oncol. 2020 Apr;21(4):497-507
pubmed: 32164906
Ann Oncol. 2019 Jan 1;30(1):124-131
pubmed: 30339194